Stocks Health care VYGR
NASDAQ · Health careVoyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. brought in $34.5M of revenue over the twelve months to June 30, 2026, down 19.1% from a year earlier. It posted a net loss of $107.7M. In fiscal 2025 capital spending exceeded operating cash flow by $135.1M. At June 30, 2026 it held $35.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Voyager Therapeutics, Inc. does
Voyager Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker VYGR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $40.4M | -$119.7M | -$2.04 | -$135.1M |
| 2024 | $80M | -$65M | -$1.13 | -$18.8M |
| 2023 | $250M | $132.3M | $2.97 | $74.7M |
| 2022 | $40.9M | -$46.4M | -$1.21 | -$15M |
| 2021 | $37.4M | -$71.2M | -$1.89 | -$55.1M |
| 2020 | $171.1M | $36.7M | $0.98 | -$108.8M |
Where VYGR ranks in Health care
Latest SEC filings
What Voyager Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 13, 2026Other event 8-K
- June 10, 2026
- June 1, 2026Other event 8-K
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 7, 2026
Questions about VYGR
What does Voyager Therapeutics, Inc. do?
Voyager Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker VYGR.
Is Voyager Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $107.7M on revenue of $34.5M.
How much revenue does Voyager Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Voyager Therapeutics, Inc. reported revenue of $34.5M. That is 19.1% less than a year earlier.
When did Voyager Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake changed from August 14, 2026.
Similar companies
Compare VYGR with
Follow VYGR
Get an email when Voyager Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow VYGR: get an email when it filesWhere the numbers come from
Financial figures are the values Voyager Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.